Patent application number | Description | Published |
20080262199 | Protein kinase C peptides for use in withdrawal - A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for εPKC or γPKC and instructions for use. | 10-23-2008 |
20090075901 | PEPTIDES FOR ACTIVATION AND INHIBITION OF DELTAPKC - Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists. | 03-19-2009 |
20090082431 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF - The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2. | 03-26-2009 |
20090143293 | Peptide inhibitors of protein kinase C gamma for pain management - Peptide sequences derived from the V5 domain of isozymes of protein kinase C for use in pain management are described. Also described are compositions comprising the peptides for treating pain and/or inducing analgesia. Methods of pain treatment and methods of identifying compounds that mimic the activity of the peptides are also described. | 06-04-2009 |
20090143309 | Isozyme-specific antagonists of protein kinase C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 06-04-2009 |
20090186814 | Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage - Methods of decreasing the extent of occlusion in the lumen of a mammalian blood vessel due to an ischemic or other hypoxic event are provided. In one form, a method includes administering to a patient in need thereof a pharmaceutically effective amount of an inhibitor of δ protein kinase C, either alone or in combination with a second therapeutic agent, and wherein the blood vessel is a blood vessel of the microvasculature. Additionally, methods of decreasing endothelial cell swelling in a mammalian blood vessel due to an ischemic or other hypoxic event are also provided. In one form, a method includes administering to a patient in need thereof a pharmaceutically effective amount of an inhibitor of δ protein kinase C, either alone or in combination with a second therapeutic agent. | 07-23-2009 |
20090192089 | Peptides for activation and inhibition of deltaPKC - Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists. | 07-30-2009 |
20090192091 | Peptide inhibitors of protein kinase C - PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described. | 07-30-2009 |
20090233869 | PSI-EPSILON RACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA - A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event. | 09-17-2009 |
20090270328 | METHODS OF INCREASING CEREBRAL BLOOD FLOW - Methods of increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. The method for increasing blood flow in such a mammalian brain blood vessel includes administering to a patient in need thereof a therapeutically effective amount of an inhibitor of δ protein kinase C. In certain embodiments, the inhibitor can be chronically administered without causing desensitization of the patient to the inhibitor. Kits for increasing blood flow in a mammalian brain blood vessel characterized by, or otherwise experiencing, decreased blood flow due to an ischemic or other hypoxic event, vasoconstriction or vasospasm following hemorrhagic stroke; due to chronic high blood pressure; and/or due to idiopathic causes are provided. | 10-29-2009 |
20090280516 | CRYSTAL STRUCTURE OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF - The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates. | 11-12-2009 |
20100048482 | COMPOSITIONS AND METHODS FOR MODULATING EPSILON PROTEIN KINASE C-MEDIATED CYTOPROTECTION - Compositions and methods for reducing ischemic cell damage and treating mitochondrial disorders using therapeutic agents derived from the V2 domain of epsilon protein kinase C (PKC) are described. | 02-25-2010 |
20100063100 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF - The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 03-11-2010 |
20100113423 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 05-06-2010 |
20100311644 | ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 12-09-2010 |
20110009331 | PROTEIN KINASE C PEPTIDES FOR USE IN WITHDRAWAL - A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for εPKC or γPKC and instructions for use. | 01-13-2011 |
20110105602 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof - The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2. | 05-05-2011 |
20110143991 | Peptides for Activation and Inhibition of Delta-PKC - Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists. | 06-16-2011 |
20120010248 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof - The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2. | 01-12-2012 |
20120028287 | Crystal Structure of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates. | 02-02-2012 |
20120172284 | ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 07-05-2012 |
20120190624 | PSI-EPSILON RACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA - A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event. | 07-26-2012 |
20130053321 | INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF - The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture. | 02-28-2013 |
20130253010 | Modulators of Aldhehyde Dehydrogenase Activity and Methods of Use Thereof - The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 09-26-2013 |
20130267501 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 10-10-2013 |
20140178352 | PEPTIDE INHIBITORS OF PROTEIN KINASE C - PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described. | 06-26-2014 |
20140178465 | METHOD AND USE OF NANO-SCALE DEVICES FOR REDUCTION OF TISSUE INJURY IN ISCHEMIC AND REPERFUSION INJURY - A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury in tissue at risk of such injury, such as heart and brain tissue. | 06-26-2014 |
20140274904 | INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF - The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture. | 09-18-2014 |
20140314734 | COMPOSITIONS AND METHODS FOR SPECIFIC REGULATION OF PYRUVATE DEHYDROGENASE KINASE - A peptide composition is provi'deo!which specifically inhibits the ability of δ protein kinase C (δPKC) to phosphor/late pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion. | 10-23-2014 |
20140323520 | Compositions and Methods for Increasing Proliferation of Adult Salivary Stem Cells - The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an indi vidual undergoing radiotherapy for head and neck cancer. | 10-30-2014 |
20140343045 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 11-20-2014 |